Reversibility of regorafenib effects in hepatocellular carcinoma cells. - Wikidata - wikimedia - TriplyDB

Reversibility of regorafenib effects in hepatocellular carcinoma cells.

Reversibility of regorafenib effects in hepatocellular carcinoma cells.

http://www.wikidata.org/entity/Q37332505

about

Targeting gastrointestinal stromal tumors: the role of regorafenib Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1 IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines.

P2860

Q26747162-DFC7F1D3-5187-4F71-AB62-3CED6EE760DE Q27345024-A3613FDB-D95D-4D5B-BC38-5400D29318EA Q33584090-66E55AC4-CDDD-49D2-B303-E441DCBAE462 Q33684043-500D3EEE-47B4-4784-9E05-397F53BC8A0E Q35639692-0D237A92-FA38-4EC8-94FD-C43B4729F13B Q36019476-98DF8EDB-A50E-41B6-B34A-A448CD44C211 Q47101174-B592FAD2-737E-478A-BE96-DC13CC7DC906

P2860

Reversibility of regorafenib effects in hepatocellular carcinoma cells.

http://www.wikidata.org/entity/Q37332505

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Reversibility of regorafenib effects in hepatocellular carcinoma cells.

@en

Reversibility of regorafenib effects in hepatocellular carcinoma cells.

@nl

type

label

Reversibility of regorafenib effects in hepatocellular carcinoma cells.

@en

Reversibility of regorafenib effects in hepatocellular carcinoma cells.

@nl

prefLabel

Reversibility of regorafenib effects in hepatocellular carcinoma cells.

@en

Reversibility of regorafenib effects in hepatocellular carcinoma cells.

@nl

P1433

Q37332505-F589D864-33B1-46EB-8106-EFF55C77A252

P1476

Q37332505-42BE33B2-50C8-4A5D-958C-2215E7ABD6F7

P2093

Q37332505-03E507A1-5D06-4FB1-9847-A972E5418111

Q37332505-3CD6B64D-E5C2-45FF-BB32-39BA31BE4ADF

Q37332505-454AB002-4F91-4333-AE8E-AE99181F7FF6

Q37332505-881189DD-717A-48B3-910B-DAEC2C132761

Q37332505-B200AB64-4BB8-49DF-8E39-3FA02E413E02

Q37332505-D35DB0B1-26C6-4F56-AC5B-2968EA3E7BC7

Q37332505-EF62C486-B821-4D04-86A9-0C973215D3AE

P2860

Q37332505-0761BEEE-05A2-473F-BFDB-76C0A05C3772

Q37332505-077A7742-295B-4173-A306-670B50ACA761

Q37332505-07EC706E-DCB8-4291-9E9F-5623E43E8914

Q37332505-10EF2881-2B42-4D60-8CC2-EF08A3E39630

Q37332505-15011E15-C4A2-46CF-8F69-B027D46061B7

Q37332505-16BD5F76-839F-4802-BFC7-5D5AED8C7EDD

Q37332505-1A3E95F8-FE96-4EE2-8BEE-BA716FF3AB15

Q37332505-22AF20D1-A87E-4BBF-9A83-815EB9E34693

Q37332505-26371CB8-83FB-4CBB-AC05-7148C543718B

Q37332505-2DC2D37E-9E9D-4BA9-8A14-E640C398E751

P2888

Q37332505-FC628293-3B47-41F0-A95D-64EDD6696F06

P304

Q37332505-DC7E9DEF-49FB-465B-BA31-513482C763B0

P31

Q37332505-66B3AB6A-5A57-4289-94E0-5C4D880925F3

P356

Q37332505-974CA03B-38DC-4292-86D6-4B42CE9E6082

P433

Q37332505-8A29AC0D-DFC3-44E0-BACA-64ED4EFCA3C4

P478

Q37332505-A75C5D05-E590-4478-8DB8-C6E509C649ED

P50

Q37332505-14A3A40A-72D0-4D0E-8DFE-2DBE8A8CBB0F

Q37332505-E6900C03-6D47-4B33-A3E5-025925C6BAB3

P577

Q37332505-DB8A0746-53D6-40EB-AEAE-231D128BEFEA

P5875

Q37332505-029ED2D8-E389-47F6-B8A2-1308653880F7

P698

Q37332505-825A85AE-BEF5-45FD-970A-F401E587DA0D

P932

Q37332505-DCA77F7A-D199-402F-96AE-19773C929F29

P356

S00280-013-2269-8

P1433

Cancer Chemotherapy and Pharmacology

P1476

Reversibility of regorafenib effects in hepatocellular carcinoma cells

@en

P2093

Aldo Cavallini

http://www.w3.org/2001/XMLSchema#string

Antonio Di Carlo

http://www.w3.org/2001/XMLSchema#string

Caterina Messa

http://www.w3.org/2001/XMLSchema#string

Catia Lippolis

http://www.w3.org/2001/XMLSchema#string

Maria G Refolo

http://www.w3.org/2001/XMLSchema#string

Roberta Rossi

http://www.w3.org/2001/XMLSchema#string

Rosalba D'Alessandro

http://www.w3.org/2001/XMLSchema#string

P2860

The functional contrariety of JNK

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Regorafenib for cancer.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

P2888

s00280-013-2269-8

P304

869-877

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-013-2269-8

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255986354

http://www.w3.org/2001/XMLSchema#string

P698

23959464

http://www.w3.org/2001/XMLSchema#string

P932

3836575

http://www.w3.org/2001/XMLSchema#string